A detailed history of Invenomic Capital Management LP transactions in Lexaria Bioscience Corp. stock. As of the latest transaction made, Invenomic Capital Management LP holds 475,773 shares of LEXX stock, worth $994,365. This represents 0.08% of its overall portfolio holdings.

Number of Shares
475,773
Previous 513,573 7.36%
Holding current value
$994,365
Previous $1.43 Million 1.68%
% of portfolio
0.08%
Previous 0.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.58 - $4.09 $97,524 - $154,602
-37,800 Reduced 7.36%
475,773 $1.45 Million
Q2 2024

Aug 14, 2024

BUY
$1.99 - $4.0 $80,212 - $161,232
40,308 Added 8.52%
513,573 $1.43 Million
Q1 2024

May 15, 2024

SELL
$1.29 - $6.25 $333,743 - $1.62 Million
-258,716 Reduced 35.34%
473,265 $1.72 Million
Q4 2023

Feb 14, 2024

SELL
$0.92 - $1.69 $29,762 - $54,673
-32,351 Reduced 4.23%
731,981 $914,000
Q3 2023

Nov 14, 2023

SELL
$0.72 - $1.11 $1,613 - $2,487
-2,241 Reduced 0.29%
764,332 $764,000
Q2 2023

Aug 14, 2023

BUY
$0.69 - $2.69 $202,494 - $789,434
293,470 Added 62.03%
766,573 $559,000
Q3 2022

Nov 14, 2022

BUY
$0.74 - $3.28 $79,839 - $353,882
107,891 Added 29.54%
473,103 $1.16 Million
Q1 2022

May 16, 2022

BUY
$2.78 - $4.7 $16,955 - $28,665
6,099 Added 1.7%
365,212 $1.06 Million
Q4 2021

Feb 11, 2022

BUY
$3.87 - $6.9 $25,905 - $46,188
6,694 Added 1.9%
359,113 $1.45 Million
Q3 2021

Nov 15, 2021

BUY
$5.39 - $8.44 $190,315 - $298,007
35,309 Added 11.13%
352,419 $2.21 Million
Q2 2021

Aug 16, 2021

BUY
$4.61 - $7.02 $96,851 - $147,483
21,009 Added 7.1%
317,110 $2.22 Million
Q1 2021

May 13, 2021

BUY
$4.26 - $8.38 $1.26 Million - $2.48 Million
296,101 New
296,101 $1.66 Million

Others Institutions Holding LEXX

About Lexaria Bioscience Corp.


  • Ticker LEXX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,951,000
  • Market Cap $12.4M
  • Description
  • Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x ...
More about LEXX
Track This Portfolio

Track Invenomic Capital Management LP Portfolio

Follow Invenomic Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invenomic Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Invenomic Capital Management LP with notifications on news.